

Munich Cancer Registry



- Incidence and Mortality
- Selection Matrix
- Homepage
- *Deutsch*

ICD-10 C21: Anal cancer

Survival

Year of diagnosis	1988-1997	1998-2014
Patients	241	1,292
Diseases	241	1,292
Cases evaluated	225	1,010
Creation date	03/02/2016	
Export date	12/23/2015	
Population	4.64 m	



Munich Cancer Registry at Munich Cancer Center
Marchioninstr. 15
Munich, 81377
Germany

<http://www.tumorregister-muenchen.de/en>

http://www.tumorregister-muenchen.de/en/facts/surv/sC21__E-ICD-10-C21-Anal-cancer-survival.pdf




Figure 1a. Relative survival of patients with anal cancer by period of diagnosis. Included in the evaluation are 1,229 cases diagnosed between 1988 and 2014.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2011, and are represented by gray diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Period of diagnosis					
	1988-1997 n=224		1998-2006 n=432		2007+ n=573	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	88.7	91.5	86.8	89.0	86.7	88.9
2	73.7	78.4	80.1	84.2	77.1	80.7
3	65.5	71.2	71.9	77.3	68.1	72.6
4	58.6	65.7	67.0	73.5	64.8	70.4
5	55.4	63.3	62.9	70.5	61.7	68.5
6	51.2	59.8	59.7	68.2	59.7	67.6
7	47.9	57.6	57.0	66.6	57.1	65.4
8	46.5	56.9	55.5	66.0		
9	44.5	55.7	52.0	63.3		
10	42.1	54.4	48.7	60.3		
11	39.7	52.2	46.1	58.4		
12	37.7	51.0	45.1	58.4		
13	36.7	50.0	43.1	57.2		
14	33.6	47.2	40.2	54.6		
15	31.0	44.5	39.0	52.7		
16	29.4	43.4				
17	28.9	43.4				
18	27.7	42.4				
19	25.7	40.4				
20	24.1	38.8				

Table 1b. Observed (obs.) and relative (rel.) survival of patients with anal cancer by period of diagnosis for period 1988-2014 (N=1,229).




Figure 2a. Survival of patients with anal cancer by gender. Included in the evaluation are 1,229 cases diagnosed between 1988 and 2014.

Years	Gender			
	Male n=391		Female n=838	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	84.6	86.9	88.3	90.7
2	73.7	77.5	79.3	83.4
3	62.2	67.2	72.1	77.3
4	59.3	65.4	66.5	72.9
5	56.4	63.5	62.6	70.1
6	51.3	59.4	60.3	68.5
7	45.9	54.4	58.5	68.0
8	44.8	53.7	56.8	67.1
9	39.2	48.4	54.8	66.3
10	35.7	45.4	51.9	64.3
11	34.9	45.1	48.5	61.6
12	34.0	45.1	46.7	60.7
13	34.0	44.8	44.6	59.1
14	30.6	42.4	41.5	56.0
15	26.6	37.0	39.9	54.7
16	23.6	34.2	38.6	54.7
17			38.6	54.7
18			36.7	54.0
19			33.6	51.1
20			32.3	49.7

Table 2b. Observed (obs.) and relative (rel.) survival of patients with anal cancer by gender for period 1988-2014 (N=1,229).




Figure 3a. Relative survival of patients with anal cancer by age category. Included in the evaluation are 1,229 cases diagnosed between 1988 and 2014.

Years	Age category							
	0-49 yrs n=210		50-59 yrs n=276		60-69 yrs n=301		70+ yrs n=442	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.6	95.4	94.0	94.2	92.6	93.5	75.1	80.3
2	85.8	86.0	85.1	85.7	85.5	87.3	63.5	72.2
3	83.6	83.7	76.3	77.4	74.1	76.8	54.0	65.3
4	79.4	80.0	76.3	77.4	68.5	71.8	46.8	59.8
5	78.7	79.2	74.2	76.2	62.9	66.9	42.5	58.4
6	75.0	75.2	73.5	75.9	61.9	66.6	36.7	54.1
7	72.4	73.3	71.6	74.4	59.6	65.3	33.0	52.1
8	70.5	70.9	69.4	72.8	59.0	65.1	31.4	52.1
9	67.2	68.7	67.7	71.7	54.0	61.3	29.2	51.8
10	67.2	68.5	63.4	68.1	52.4	60.2	24.9	49.5

Table 3b. Observed (obs.) and relative (rel.) survival of patients with anal cancer by age category for period 1988-2014 (N=1,229).




Figure 4a. Relative survival of patients with anal cancer by UICC. For 1,038 of 1,229 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 989 cases an evaluable classification was established. The grey line represents the subgroup of 240 patients with missing values regarding UICC (19.5% of 1,229 patients, the percent values of all other categories are related to n=989).

Years	UICC											
	I n=197		II n=411		IIIA n=184		IIIB n=126		IV n=71		NA/NOS n=240	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	99.5	99.7	89.9	92.0	89.3	91.4	90.9	92.5	52.9	52.6	78.7	81.7
2	91.4	95.0	84.5	88.5	75.7	79.8	75.6	78.2	32.1	32.6	69.5	73.9
3	87.6	92.6	76.9	82.1	63.4	68.3	58.2	62.3			63.0	69.1
4	82.4	88.5	72.8	79.3	57.2	63.6	58.2	62.3			57.2	63.7
5	79.6	86.7	69.3	77.0	51.5	59.2	51.7	57.5			55.0	62.9
6	73.3	81.5	67.6	76.2	48.0	56.1	47.3	53.9			51.8	60.1
7	72.5	81.3	64.7	74.9	42.6	51.8	43.4	48.5			49.1	57.9
8	72.5	81.3	62.1	73.0	40.6	49.8	40.7	46.4			48.4	57.8
9	70.2	81.3	58.3	69.9	36.2	46.4					46.7	56.9
10	65.5	79.9	55.1	67.4	36.2	46.4					41.3	52.0

Table 4b. Observed (obs.) and relative (rel.) survival of patients with anal cancer by UICC for period 1988-2014 (N=989).




Figure 4c. Relative survival of patients with anal cancer by UICC. For 842 of 1,005 cases diagnosed between 1998 and 2014 valid data could be obtained for this item. For a total of 802 cases an evaluable classification was established. The grey line represents the subgroup of 203 patients with missing values regarding UICC (20.2% of 1,005 patients, the percent values of all other categories are related to n=802).

Years	UICC											
	I n=158		II n=326		IIIA n=145		IIIB n=115		IV n=58		NA/NOS n=203	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	99.4	99.6	89.7	91.7	90.7	92.5	91.0	92.4	50.8	49.9	77.4	80.1
2	93.9	97.3	85.5	89.2	77.1	80.8	77.7	80.2	37.2	37.7	67.9	71.8
3	89.0	94.1	78.4	83.3	64.4	69.0	61.8	65.8			61.3	66.7
4	84.6	90.8	74.2	80.5	60.7	66.4	61.8	65.8			56.0	61.7
5	81.9	89.0	71.1	78.6	55.2	62.9	54.4	60.0			53.3	60.3
6	75.3	83.5	69.1	77.6	55.2	62.9	49.3	55.6			50.7	58.0
7	74.1	83.4	67.9	77.6	47.4	57.3	44.7	48.7			49.0	56.5
8	74.1	83.4	65.9	76.4	44.6	53.9					47.9	56.3
9	72.4	83.4	61.4	72.5	39.7	50.5					45.5	54.1
10	66.6	81.3	57.7	69.2	39.7	50.5					40.4	48.8

Table 4d. Observed (obs.) and relative (rel.) survival of patients with anal cancer by UICC for period 1998-2014 (N=802).




Figure 4e. Relative survival of patients with anal cancer by TNM staging. For 1,038 of 1,229 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 933 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potentially considered in more than one subgroup. The grey line represents the subgroup of 296 patients with missing values regarding TNM staging (24.1 % of 1,229 patients, the percent values of all other categories are related to n=933).

TNM staging														
Years	T1M0 n=190		T2M0 n=306		T3M0 n=234		T4M0 n=87		NOM0 n=451		N+M0 n=232		NXM0 n=107	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	99.5	99.7	92.3	94.1	90.1	92.3	83.0	84.7	94.1	96.1	92.7	94.6	86.8	89.3
2	90.9	94.7	85.4	88.9	81.0	85.3	64.2	67.0	87.8	91.5	79.3	82.7	73.1	77.5
3	85.0	90.2	77.5	82.0	69.7	75.3	51.9	55.2	81.0	86.0	64.4	68.5	66.7	71.4
4	80.8	87.1	72.2	78.1	66.4	73.5	50.5	54.6	76.7	83.1	60.9	66.5	61.2	67.4
5	78.6	86.2	67.3	74.2	62.0	70.2	43.7	49.3	73.5	81.1	54.0	60.4	58.8	66.4
6	72.8	81.5	65.9	73.4	59.1	68.1	41.8	48.0	70.8	79.8	50.9	57.6	57.5	65.3
7	71.9	81.3	63.0	72.2	53.7	63.1	37.2	44.2	67.8	78.4	45.6	52.5	54.8	64.5
8	71.9	81.3	61.1	71.0	51.2	61.4			65.8	77.3	43.5	51.1	53.3	63.6
9	69.6	81.3	57.6	68.1	47.4	58.7			62.6	75.3	38.5	47.0	51.7	63.3
10	65.9	81.3	55.3	66.6	44.3	55.5			59.5	73.5	38.5	46.9	50.1	62.3

<i>cont'd</i>	TNM staging			
	M1 n=71		NA/NOS n=296	
	obs. %	rel. %	obs. %	rel. %
Years				
0	100.0	100.0	100.0	100.0
1	52.9	52.6	80.0	82.9
2	32.1	32.6	72.5	77.1
3			65.4	71.5
4			59.4	66.5
5			57.3	65.4
6			52.5	61.1
7			50.9	60.1
8			49.7	59.5
9			46.9	57.4
10			41.7	52.5

Table 4f. Observed (obs.) and relative (rel.) survival of patients with anal cancer by TNM staging for period 1988-2014 (N=1,678).




Figure 4g. Relative survival of patients with anal cancer by TNM staging. For 842 of 1,005 cases diagnosed between 1998 and 2014 valid data could be obtained for this item. For a total of 757 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potentially considered in more than one subgroup. The grey line represents the subgroup of 248 patients with missing values regarding TNM staging (24.7 % of 1,005 patients, the percent values of all other categories are related to n=757).

TNM staging														
	T1M0 n=154		T2M0 n=248		T3M0 n=193		T4M0 n=69		N0M0 n=355		N+M0 n=203		NXM0 n=79	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	99.4	99.6	92.9	94.7	90.1	92.0	86.1	87.7	94.8	96.7	92.7	94.4	89.8	92.1
2	92.9	96.6	87.7	91.2	81.7	85.6	67.0	69.7	89.7	93.3	80.5	83.7	76.4	81.0
3	85.2	90.7	79.6	84.1	72.0	77.2	54.7	57.7	82.8	87.7	66.8	71.1	69.0	73.7
4	81.6	88.0	75.4	81.2	69.2	75.7	52.7	56.4	78.5	84.6	65.4	70.6	62.7	69.4
5	79.6	87.3	70.1	77.2	65.0	72.8	45.7	51.2	75.7	83.1	57.9	64.5	61.0	69.2
6	72.8	81.5	68.9	76.4	61.9	70.4	45.7	50.5	72.8	81.5	55.9	63.0	59.1	68.1
7	71.5	81.3	67.2	76.4	56.6	65.4			71.1	81.1	49.3	56.5	56.9	67.6
8	71.5	81.3	64.5	74.4	55.5	65.0			69.2	80.5	46.6	54.5	54.6	66.1
9	69.8	81.3	59.1	69.0	51.3	62.0			65.5	77.7	40.2	48.9	54.6	66.0
10	65.9	81.3	57.8	68.4	46.3	56.2			62.9	76.0	40.2	48.4	52.0	65.0

<i>cont'd</i>	TNM staging			
	M1 n=58		NA/NOS n=248	
	obs. %	rel. %	obs. %	rel. %
Years				
0	100.0	100.0	100.0	100.0
1	50.8	49.9	77.4	80.0
2	37.2	37.7	70.0	74.0
3			63.2	68.5
4			58.4	64.6
5			56.2	63.3
6			53.0	60.6
7			51.6	59.8
8			50.8	59.7
9			47.8	57.1
10			42.5	51.6

Table 4h. Observed (obs.) and relative (rel.) survival of patients with anal cancer by TNM staging for period 1998-2014 (N=1,359).




Figure 5a. Time to first progression of 948 patients with anal cancer diagnosed between 1998 and 2014 (M0 only in solid cancers) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

Years	Type of progression						
	Any type (CI)	Any type (1-KM)	Distant metastasis (CI)	Distant metast. (1-KM)	Locoreg. relapse (CI)	Locoreg. rel. (1-KM)	NOS (CI)
	n=948 %	n=948 %	n=948 %	n=948 %	n=948 %	n=948 %	n=948 %
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	16.8	17.4	6.6	7.1	5.9	6.5	3.2
2	26.4	27.7	12.8	14.0	10.2	11.6	4.7
3	30.1	31.6	15.8	17.6	12.4	14.4	5.0
4	31.7	33.4	17.6	19.9	13.4	15.7	5.1
5	32.8	34.7	18.7	21.3	14.0	16.6	5.1
6	33.8	35.9	19.1	21.8	14.4	17.0	5.3
7	34.0	36.2	19.7	22.7	14.6	17.4	5.3
8	34.5	36.8	20.2	23.4	14.8	17.8	5.3
9	35.3	37.8	20.8	24.3	14.8	17.8	5.3
10	35.3	37.8	21.1	24.8	14.8	17.8	5.3

Type of progression	
<i>cont'd</i>	NOS (1-KM) n=948
Years	%
0	0.0
1	3.5
2	5.4
3	5.8
4	6.0
5	6.0
6	6.2
7	6.2
8	6.2
9	6.2
10	6.2

Table 5b. Time to first progression of patients with anal cancer for period 1998-2014 (N=948).




Figure 5c. Observed post-progression survival of 268 patients with anal cancer diagnosed between 1998 and 2014. These 268 patients with documented progression events during their course of disease represent 26.7 % of the totally 1,005 evaluated cases (incl. M1, n=57, 5.7 %). Patients with cancer relapse documented via death certificates only were excluded (n=91, 9.1 %). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potentially considered in more than one subgroup.

Years	Type of progression			
	Any type n=268 %	Distant metastasis n=167 %	Locoregional relapse n=130 %	NOS n=47 %
0	100.0	100.0	100.0	100.0
1	58.4	46.1	61.7	67.4
2	37.9	27.3	41.7	42.7
3	29.1	22.3	34.1	
4	23.8	17.4	27.9	
5	22.3		26.4	
6	22.3		26.4	
7	20.6			
8	17.6			

Table 5d. Observed post-progression survival of patients with anal cancer for period 1998-2014 (N=268).




Figure 5e. Observed post-progression (distant metastasis) survival of 203 patients with anal cancer diagnosed between 1988 and 2014 by period of progression.

Years	Period of progression		
	1988-1997 n=29	1998-2006 n=62	2007+ n=112
0	100.0	100.0	100.0
1		43.3	49.4
2			30.8
3			26.7

Table 5f. Observed post-progression (distant metastasis) survival of patients with anal cancer for period 1988-2014 by period of progression (N=203).

Shortcuts

MCR Munich Cancer Registry, Germany

NCI National Cancer Institute, USA

SEER Surveillance, Epidemiology, and End Results, USA

UICC Union for International Cancer Control, Geneva

DCO Death certificate only Death certificate provides the only notification to the registry.

NA Not available

NOS Not otherwise specified

OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate)

Date of entry: diagnosis
Event: death from any cause

RS Relative survival Survival compared to “general population”, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival

AS Assembled survival Assembled chart of observed, expected, relative survival

CS Conditional survival Survival probability under the condition of surviving a given period of time

TTP Time to progression Time to first progression / relapse
Date of entry: diagnosis
Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression

1-KM 1 minus Kaplan-Meier estimator
 (“inverse” Kaplan-Meier estimator)

CI Cumulative incidence
Death as competing risk (according to Kalbfleisch und Prentice)

PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate)
Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression
Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C21: Anal cancer [Internet]. 2016 [updated 2016 Mar 2; cited 2016 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/sC21__E-ICD-10-C21-Anal-cancer-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

Fig./Tbl.	Page
1a Relative survival by period of diagnosis (chart)	2
1b Survival by period of diagnosis (table)	3
2a Survival by gender (chart)	4
2b Survival by gender (table)	4
3a Relative survival by age category (chart)	5
3b Survival by age category (table)	5
4a Relative survival by UICC 1988+ (chart)	6
4b Survival by UICC 1988+ (table)	6
4c Relative survival by UICC 1998+ (chart)	7
4d Survival by UICC 1998+ (table)	7
4e Relative survival by TNM staging 1988+ (chart)	8
4f Survival by TNM staging 1988+ (table)	8
4g Relative survival by TNM staging 1998+ (chart)	10
4h Survival by TNM staging 1998+ (table)	10
5a Time to first progression (chart)	12
5b Time to first progression (table)	12
5c Observed post-progression survival (chart)	14
5d Observed post-progression survival (table)	14
5e Observed post-progression survival by period of progression (chart)	15
5f Observed post-progression survival by period of progression (table)	15